Junlin Liu
Junlin Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Guo-Zhong Tao
Department of Surgery, Divison of Pediatric Surgery, Stanford University School of Medicine, Stanford, CA, United States
2 shared publications - Jingjing Wei
Department of Pediatrics, Shanxi Medical University, Taiyuan, People’s Republic of China
2 shared publications - Karl G. Sylvester
Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA
2 shared publications - Kewei Wang
Department of Gastrointestinal Surgery, the First Affiliated Hospital of China Medical University, China
2 shared publications - Baohui Xu
Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA
1 shared publication - Bomi Framroze
Department of Surgery, Stanford University School of Medicine, Stanford, CA 94304, USA
1 shared publication
Latest Publications
- Open Access
- 1 June 2025
- Published by Tsinghua University Press in Aging Research
- Vol. 3 (2) , 9340049
Analysis of age-related changes and clinical characteristics of synchronous gastric-rectal signet ring cell carcinoma: a case report and literature review
As age increases, the risk of gastrointestinal malignancies increases significantly, and the probability of the synchronous occurrence of rectal cancer and gastric cancer also increases. Among these, cases of dual primary signet ring cell carcinoma are exceptionally rare and demonstrate greater invasive potential. This article reports a case of synchronous rectal-gastric signet ring cell carcinoma in an elderly patient, which rapidly progressed to death within a short period due to age-related deterioration in tumor biological behavior, multisystem metastasis, and chemoresistance. Through multidisciplinary diagnosis and treatment combined with molecular pathological analysis, this study has investigated the impact of age-related changes on the aggressiveness, therapeutic response, and prognosis of signet ring cell carcinoma, providing evidence-based support for early screening and personalized treatment in elderly patients.
- 1 June 2025
- Published by Tsinghua University Press in Aging Research
- Vol. 3 (2) , 9340049
Open AccessAnalysis of age-related changes and clinical characteristics of synchronous gastric-rectal signet ring cell carcinoma: a case report and literature review
As age increases, the risk of gastrointestinal malignancies increases significantly, and the probability of the synchronous occurrence of rectal cancer and gastric cancer also increases. Among these, cases of dual primary signet ring cell carcinoma are exceptionally rare and demonstrate greater invasive potential. This article reports a case of synchronous rectal-gastric signet ring cell carcinoma in an elderly patient, which rapidly progressed to death within a short period due to age-related deterioration in tumor biological behavior, multisystem metastasis, and chemoresistance. Through multidisciplinary diagnosis and treatment combined with molecular pathological analysis, this study has investigated the impact of age-related changes on the aggressiveness, therapeutic response, and prognosis of signet ring cell carcinoma, providing evidence-based support for early screening and personalized treatment in elderly patients.
- Open Access
- 14 March 2023
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2023, 1-8
Fecal Keratin 8 Is a Noninvasive and Specific Marker for Intestinal Injury in Necrotizing Enterocolitis
Specific biomarkers of intestinal injury associated with necrotizing enterocolitis (NEC) are needed to diagnose and monitor intestinal mucosal injury and recovery. This study aims to develop and test a modified enzyme-linked immunosorbent assay (ELISA) protocol to detect the total keratin 8 (K8) in the stool of newborns with NEC and investigate the clinical value of fecal K8 as a marker of intestinal injury specifically associated with NEC. We collected fecal samples from five newborns with NEC and five gestational age-matched premature neonates without NEC at the Lucile Packard Children’s Hospital Stanford and Washington University School of Medicine, respectively. Fecal K8 levels were measured using a modified ELISA protocol and Western blot, and fecal calprotectin was measured using a commercial ELISA kit. Clinical data, including gestational age, birth weight, Bell stage for NEC, feeding strategies, total white blood cell (WBC) count, and other pertinent clinical variables, were collected and analyzed. Fecal K8 levels were significantly higher in the pre-NEC group (1–2 days before diagnosis of NEC) and NEC group than those in the non-NEC group ( , ). Moreover, fecal K8 was relatively higher at the onset of NEC and declined after the resolution of the disease ( ). Results with similar trends to fecal K8 were also seen in fecal calprotectin ( ), but not seen in total WBC count ( ). In conclusion, a modified ELISA protocol for the total K8 protein was successfully developed for the detection of fecal K8 in the clinical setting of premature newborns with NEC. Fecal K8 is noted to be significantly increased in premature newborns with NEC and may, therefore, serve as a noninvasive and specific marker for intestinal epithelial injury associated with NEC.
- 14 March 2023
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2023, 1-8
Open AccessFecal Keratin 8 Is a Noninvasive and Specific Marker for Intestinal Injury in Necrotizing Enterocolitis
Specific biomarkers of intestinal injury associated with necrotizing enterocolitis (NEC) are needed to diagnose and monitor intestinal mucosal injury and recovery. This study aims to develop and test a modified enzyme-linked immunosorbent assay (ELISA) protocol to detect the total keratin 8 (K8) in the stool of newborns with NEC and investigate the clinical value of fecal K8 as a marker of intestinal injury specifically associated with NEC. We collected fecal samples from five newborns with NEC and five gestational age-matched premature neonates without NEC at the Lucile Packard Children’s Hospital Stanford and Washington University School of Medicine, respectively. Fecal K8 levels were measured using a modified ELISA protocol and Western blot, and fecal calprotectin was measured using a commercial ELISA kit. Clinical data, including gestational age, birth weight, Bell stage for NEC, feeding strategies, total white blood cell (WBC) count, and other pertinent clinical variables, were collected and analyzed. Fecal K8 levels were significantly higher in the pre-NEC group (1–2 days before diagnosis of NEC) and NEC group than those in the non-NEC group ( , ). Moreover, fecal K8 was relatively higher at the onset of NEC and declined after the resolution of the disease ( ). Results with similar trends to fecal K8 were also seen in fecal calprotectin ( ), but not seen in total WBC count ( ). In conclusion, a modified ELISA protocol for the total K8 protein was successfully developed for the detection of fecal K8 in the clinical setting of premature newborns with NEC. Fecal K8 is noted to be significantly increased in premature newborns with NEC and may, therefore, serve as a noninvasive and specific marker for intestinal epithelial injury associated with NEC.
- Open Access
- 13 September 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (9) , 1287
Soluble Protein Hydrolysate Ameliorates Gastrointestinal Inflammation and Injury in 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis in Mice
Inflammatory bowel diseases (IBD) are chronic, recurring gastrointestinal diseases that severely impair health and quality of life. Although therapeutic options have significantly expanded in recent years, there is no effective therapy for a complete and permanent cure for IBD. Well tolerated dietary interventions to improve gastrointestinal health in IBD would be a welcome advance especially with anticipated favorable tolerability and affordability. Soluble protein hydrolysate (SPH) is produced by the enzymatic hydrolysis of commercial food industry salmon offcuts (consisting of the head, backbone and skin) and contains a multitude of bioactive peptides including those with anti-oxidant properties. This study aimed to investigate whether SPH ameliorates gastrointestinal injury in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced mouse colitis model. Mice were randomly assigned to four groups: Control (no colitis), Colitis, Colitis/CP (with control peptide treatment), and Colitis/SPH (with SPH treatment). Colitis was induced by cutaneous sensitization with 1% TNBS on day −8 followed by 2.5% TNBS enema challenge on day 0. Control peptides and SPH were provided to the mice in the Colitis/CP or Colitis/SPH group respectively by drinking water at the final concentration of 2% w/v daily from day −10 to day 4. Then, the colon was harvested on day 4 and examined macro- and microscopically. Relevant measures included disease activity index (DAI), colon histology injury, immune cells infiltration, pro- and anti-inflammatory cytokines and anti-oxidative gene expression. It was found that SPH treatment decreased the DAI score and colon tissue injury when compared to the colitis-only and CP groups. The protective mechanisms of SPH were associated with reduced infiltration of CD4+ T, CD8+ T and B220+ B lymphocytes but not macrophages, downregulated pro-inflammatory cytokines (tumor necrosis factor-α and interleukin-6), and upregulated anti-inflammatory cytokines (transforming growth factor-β1 and interleukin-10) in the colon tissue. Moreover, the upregulation of anti-oxidative genes, including ferritin heavy chain 1, heme oxygenase 1, NAD(P)H quinone oxidoreductase 1, and superoxide dismutase 1, in the colons of colitis/SPH group was observed compared with the control peptide treatment group. In conclusion, the protective mechanism of SPH is associated with anti-inflammatory and anti-oxidative effects as demonstrated herein in an established mice model of colitis. Clinical studies with SPH as a potential functional food for the prevention or as an adjuvant therapy in IBD may add an effective and targeted diet-based approach to IBD management in the future.
- 13 September 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (9) , 1287
Open AccessSoluble Protein Hydrolysate Ameliorates Gastrointestinal Inflammation and Injury in 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis in Mice
Inflammatory bowel diseases (IBD) are chronic, recurring gastrointestinal diseases that severely impair health and quality of life. Although therapeutic options have significantly expanded in recent years, there is no effective therapy for a complete and permanent cure for IBD. Well tolerated dietary interventions to improve gastrointestinal health in IBD would be a welcome advance especially with anticipated favorable tolerability and affordability. Soluble protein hydrolysate (SPH) is produced by the enzymatic hydrolysis of commercial food industry salmon offcuts (consisting of the head, backbone and skin) and contains a multitude of bioactive peptides including those with anti-oxidant properties. This study aimed to investigate whether SPH ameliorates gastrointestinal injury in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced mouse colitis model. Mice were randomly assigned to four groups: Control (no colitis), Colitis, Colitis/CP (with control peptide treatment), and Colitis/SPH (with SPH treatment). Colitis was induced by cutaneous sensitization with 1% TNBS on day −8 followed by 2.5% TNBS enema challenge on day 0. Control peptides and SPH were provided to the mice in the Colitis/CP or Colitis/SPH group respectively by drinking water at the final concentration of 2% w/v daily from day −10 to day 4. Then, the colon was harvested on day 4 and examined macro- and microscopically. Relevant measures included disease activity index (DAI), colon histology injury, immune cells infiltration, pro- and anti-inflammatory cytokines and anti-oxidative gene expression. It was found that SPH treatment decreased the DAI score and colon tissue injury when compared to the colitis-only and CP groups. The protective mechanisms of SPH were associated with reduced infiltration of CD4+ T, CD8+ T and B220+ B lymphocytes but not macrophages, downregulated pro-inflammatory cytokines (tumor necrosis factor-α and interleukin-6), and upregulated anti-inflammatory cytokines (transforming growth factor-β1 and interleukin-10) in the colon tissue. Moreover, the upregulation of anti-oxidative genes, including ferritin heavy chain 1, heme oxygenase 1, NAD(P)H quinone oxidoreductase 1, and superoxide dismutase 1, in the colons of colitis/SPH group was observed compared with the control peptide treatment group. In conclusion, the protective mechanism of SPH is associated with anti-inflammatory and anti-oxidative effects as demonstrated herein in an established mice model of colitis. Clinical studies with SPH as a potential functional food for the prevention or as an adjuvant therapy in IBD may add an effective and targeted diet-based approach to IBD management in the future.